Latest news with #GoodRx
Forbes
14 hours ago
- Business
- Forbes
Why Public Trust In AI Echoes The Pixel Era
Jacques Nack, Chief Executive Officer at JNN Group Inc., is a trailblazer in cloud security, compliance, and risk management. When I first wrote about the $1.5 million FTC fine against GoodRx for allegedly mishandling health data through tracking pixels, it served as a wake-up call about the liabilities of passive technologies. Today, we face a sequel—this time starring artificial intelligence. The same companies scrambling to contain pixel-related lawsuits now risk repeating history by adopting AI recklessly. Consider the parallels: • Pixels: Websites have embedded pixels without consent, sparking a rush of Video Privacy Protection Act (VPPA) class actions. • AI: Enterprises are deploying AI systems without governance, inviting regulatory avalanches under the EU AI Act. The pattern is clear. Both technologies promised transformative value but became liability time bombs when deployed without guardrails. The Pixel Playbook Revisited: AI's Looming Reckoning Fast forward to 2025: A major insurer is facing a proposed class action lawsuit alleging it used artificial intelligence tools, rather than medical professionals, to deny coverage for medically necessary care. This isn't just hypothetical. The lack of transparency and accountability in how AI systems process sensitive information is already leading to serious consequences. According to Stanford University's "Artificial Intelligence Index Report 2025", organizations are facing a surge in AI-related privacy incidents, with many lacking sufficient safeguards. Many organizations now use AI tools that process employee or customer data in ways that would fail basic pixel-era consent standards. Regulators are responding. The EU AI Act now places recruitment platforms using AI in the 'high risk' category, subjecting them to potential fines of up to €35 million (about $40 million) or 7% of global annual turnover for violations related to bias or lack of transparency. While no fine of this scale has yet been imposed, the law's unprecedented penalty structure demonstrates that European regulators view ungoverned AI as an even greater liability than the pixel-era privacy crises. Governance: 'The Antidote' To 'AI Theater' The pixel crisis taught us that it's not just compliance—it's a matter of culture, rather than a matter of a checkbox. Companies that viewed pixel management as an IT task rather than a strategic imperative paid the price. AI demands the same paradigm shift. Case in point: The Mayo Clinic's governance-driven approach combines privacy-preserving federated learning, encrypted data management and rigorous model validation tools to ensure AI systems are transparent, fair and accountable. Their Platform_Validate solution tests for bias and accuracy across diverse populations, while AI initiatives are integrated into clinical workflows to directly improve diagnostics and patient outcomes, not just operational efficiency. Contrast this with a retail client I advised last month: Their rushed ChatGPT integration scraped customer service transcripts without consent, creating a discovery nightmare in an ongoing privacy suit. The lesson? Governance isn't innovation's enemy—it's the foundation. Measuring What Matters: ROI Beyond Hype Pixel litigation exposed the myth of "free data." Companies learned the hard way that poorly managed user tracking erased years of marketing return on investment (ROI) through fines and reputational damage. AI faces an identical reckoning. Consider three critical points: 1. Risk-Adjusted ROI: A healthcare AI might show 300% efficiency gains but cost 400% in legal settlements if trained on noncompliant data. 2. Trust Equity: The Microsoft Tay chatbot debacle is now a classic example of AI risk and trust equity loss—a hidden cost rarely factored into AI budgets. 3. Regulatory Preparedness: In my experience, firms aligning their systems with NIST's framework report improved audit readiness, turning compliance into a competitive advantage. The Strategic Path Forward History offers a blueprint. Just as leading companies transformed pixel management into privacy-by-design programs, AI demands: • C-Suite Ownership: Appoint AI governance leads with board reporting authority. • Third-Pressure Testing: Require vendors to disclose the data sources used to train their AI models, just as was once expected of 'pixel vendors' in the digital advertising ecosystem. • Transparency Protocols: Implement "explainability as a service" tools that demystify AI decisions for regulators and users. The alternative? Watching history repeat. When pixel lawsuits surged, organizations with mature data maps limited liability through precise data minimization. Today's AI pioneers are those applying these lessons to model training logs and inference audits. Writing AI's Next Chapter The pixel era's central lesson wasn't about technology—it was about trust. Companies that treated user data as someone else's problem became case studies. As AI's capabilities (and risks) dwarf those of tracking pixels, the stakes have never been higher. Regulators are watching. The EU's AI Act now classifies hiring and healthcare tools as 'high risk,' mandating the same rigor once reserved for pixel consent management. Meanwhile, some plaintiffs' firms have added "AI negligence" to their playbooks. But there's light ahead. Organizations embracing governance as innovation's partner—not its bureaucrat—are achieving ROI that reckless adopters can't touch. They're the Mayo Clinics, not the Theranoses, of AI. The question isn't whether your AI strategy needs governance. It's whether you'll implement it before your competitors weaponize it against you. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Time of India
3 days ago
- Entertainment
- Time of India
Patar's poetry finds new script, techie decodes him for other Pb
Chandigarh: Motivated by a love for language and growing demand from readers in Pakistan, Melbourne-based Tejinder Singh has taken it upon himself to translate the works of iconic Punjabi poet Surjit Patar into Shahmukhi, the script used in West Punjab. The 48-year-old computing professional who moved to Australia two decades ago began the project by translating Khudkushi (suicide), one of Patar's acclaimed poems, into Shahmukhi and sharing it on X (formerly Twitter). "I'm surprised to find that Patar remains untranslated into Shahmukhi or English," he wrote. "I start a humble effort to bridge these languages, translating his works one poem at a time." His effort drew praise from British MP Preet Kaur Gill, who posted the original Gurmukhi version in appreciation. Born at Bhagowal village in Punjab's Gurdaspur district, Tejinder Singh said the idea had struck him after repeated requests from readers in Pakistani Punjab. "They want to read Patar, and it's disheartening that his poetry remains inaccessible there largely due to script barriers," he said. Even though trained in computing — with a bachelor's degree from India and a master's from Australia — Tejinder Singh taught himself Shahmukhi using open resources. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live Updates: Insurance Coverage GIP & GLP-1 Agonists GoodRx Learn More Undo "Shahmukhi is similar to Urdu, but with an extra layer of diacritics for Punjabi sounds," he explained. While he uses artificial intelligence tools during the process, he says he reviews and refines each translation manually to preserve the original poem's emotional and literary essence. The translator believes literature is key to rebuilding lost cultural ties between East and West Punjab. "There are about 3 crore Punjabis in Indian Punjab, but 13 crore in Pakistani Punjab. Our shared literature deserves to be read and loved across the border," he said. Calling his initiative a personal passion project, Tejinder Singh plans to continue translating Patar's poetry to ensure the late poet's work transcends scripts, borders, and generations. One poem at a time, he'll send, a bridge of ink the border can't end. MSID:: 122955215 413 |
New York Post
24-07-2025
- Health
- New York Post
Ambien use not recommended for people with these occupations, according to doctors
Ambien is under scrutiny following recent claims about Joe Biden's use of the popular sleep aid. In an interview with YouTube host Andrew Callaghan that was released Monday, Hunter Biden alleged that the sleeping pills could have contributed to his father's apparent cognitive struggles during the first 2024 presidential debate. 'He's 81 years old. He's tired as s–t. They give him Ambien to be able to sleep,' the former president's son claimed. 'He gets up on stage, and he looks like he's a deer in the headlights. And it feeds into a f–king story that anybody wants to tell.' Amid these claims, some have voiced concerns about the former president's possible use of the drug, which has been linked to memory problems and daytime grogginess. Ambien (generic name zolpidem), a prescription medication for insomnia, is intended only for short-term use, according to GoodRx. Some of the more serious and rare side effects can include hallucinations, 'abnormal thinking and behavior,' and 'possible increased risk of dementia in older adults.' During a Tuesday appearance on 'Fox and Friends,' political reporter and author Salena Zito commented on the president's alleged use of Ambien. 'For the guy who's supposed to answer the 3 a.m. phone calls — it's bewildering,' she said. 'I can't imagine a doctor prescribing that to a president, and I can't imagine that this has been a secret.' 3 Ambien is under scrutiny following recent claims about Joe Biden's use of the popular sleep aid. Getty Images Who should not take Ambien? The medication's prescription information warns of 'potential impairment of activities requiring complete mental alertness,' including operating machinery or driving a motor vehicle, which can last until the day after taking it. The Federal Aviation Administration (FAA) states that pilots and aircrews should not fly within 24 hours of taking a sleep aid. 'All currently available sleep aids, both prescription and OTC, can cause impairment of mental processes and reaction times, even when the individual feels fully awake,' the agency states in its 'Do Not Fly' guidelines. Heavy equipment and machinery operators should also refrain from operating machinery within seven to eight hours — or ideally until the following day — after taking the drug due to delayed cognitive and motor recovery, according to the medication's prescribing info. Commercial truck drivers should adhere to these same cautions. For drivers taking a prescription sleep aid, the Federal Motor Carrier Safety Administration states that a medical examiner will review each medication and request a letter from the prescribing doctor to determine whether the drug will 'adversely affect safe operation' of a commercial motor vehicle. 3 Former President Biden falls on stage during the 2023 United States Air Force Academy Graduation Ceremony at Falcon Stadium, Thursday, June 1, 2023, at the United States Air Force Academy in Colorado Springs, Colo. AP Experts also urge caution for law enforcement, first responders and medical workers in acute healthcare settings due to the risk of slowed reaction time, 'cognitive fog' and errors in judgment. 'I think there may be times when physicians require sleep aids, but not in a way where they could interfere with performance during procedures,' Dr. Marc Siegel, Fox News' senior medical analyst, told Fox News Digital. For military personnel, the Department of Defense (DOD) requires service members to get a minimum of seven hours of sleep per night for 'military readiness.' 3 Hunter Biden alleged that the sleeping pills could have contributed to his father's apparent cognitive struggles during the first 2024 presidential debate. Bloomberg News The DOD has also cautioned about the 'physiological and cognitive negative side effects' of sleep aids. Fox News Digital reached out to Joe Biden's representatives and to Cosette Pharmaceuticals, the current manufacturer of Ambien, for comment.
Fox News
24-07-2025
- Health
- Fox News
Ambien use not recommended for people with certain occupations, doctors say
Print Close By Melissa Rudy Published July 24, 2025 Ambien is under scrutiny following recent claims about Joe Biden's use of the popular sleep aid. In an interview with YouTube host Andrew Callaghan that was released Monday, Hunter Biden alleged that the sleeping pills could have contributed to his father's apparent cognitive struggles during the first 2024 presidential debate. "He's 81 years old. He's tired as s---. They give him Ambien to be able to sleep," the former president's son claimed. "He gets up on stage, and he looks like he's a deer in the headlights. And it feeds into a f------ story that anybody wants to tell." AMBIEN UNDER SCRUTINY AMID CLAIMS JOE BIDEN HAD BEEN TAKING SLEEP DRUG Amid these claims, some have voiced concerns about the former president's possible use of the drug, which has been linked to memory problems and daytime grogginess. Ambien (generic name zolpidem), a prescription medication for insomnia, is intended only for short-term use, according to GoodRx. Some of the more serious and rare side effects can include hallucinations, "abnormal thinking and behavior" and "possible increased risk of dementia in older adults." During a Tuesday appearance on "Fox and Friends," political reporter and author Salena Zito commented on the president's alleged use of Ambien. DOCTORS EXPRESS CONCERN ABOUT BIDEN'S APPARENT COGNITIVE ISSUES DURING DEBATE: 'TROUBLING INDICATORS' "For the guy who's supposed to answer the 3 a.m. phone calls — it's bewildering," she said. "I can't imagine a doctor prescribing that to a president, and I can't imagine that this has been a secret." Who should not take Ambien? The medication's prescription information warns of "potential impairment of activities requiring complete mental alertness," including operating machinery or driving a motor vehicle, which can last until the day after taking it. The Federal Aviation Administration (FAA) states that pilots and aircrew should not fly within 24 hours of taking a sleep aid. "For the guy who's supposed to answer the 3 a.m. phone calls — it's bewildering." "All currently available sleep aids, both prescription and OTC, can cause impairment of mental processes and reaction times, even when the individual feels fully awake," the agency states in its "Do Not Fly" guidelines. Heavy equipment and machinery operators should also refrain from operating machinery within seven to eight hours — or ideally until the following day — after taking the drug due to delayed cognitive and motor recovery, according to the medication's prescribing info. CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER Commercial truck drivers should adhere to these same cautions. For drivers taking a prescription sleep aid, the Federal Motor Carrier Safety Administration states that a medical examiner will review each medication and request a letter from the prescribing doctor to determine whether the drug will "adversely affect safe operation" of a commercial motor vehicle. Experts also urge caution for law enforcement, first responders and medical workers in acute healthcare settings due to the risk of slowed reaction time, "cognitive fog" and errors in judgment. "I think there may be times when physicians require sleep aids, but not in a way where they could interfere with performance during procedures," Dr. Marc Siegel, Fox News' senior medical analyst, told Fox News Digital. CLICK HERE TO GET THE FOX NEWS APP For military personnel, the Department of Defense (DOD) requires service members to get a minimum of seven hours of sleep per night for "military readiness." The DOD has also cautioned about the "physiological and cognitive negative side effects" of sleep aids. For more Health articles, visit Fox News Digital reached out to Joe Biden's representatives and to Cosette Pharmaceuticals, the current manufacturer of Ambien, for comment. Print Close URL
Globe and Mail
19-07-2025
- Business
- Globe and Mail
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc.
The law firm of Kahn Swick & Foti, LLC ('KSF') has commenced an investigation into GoodRx Holdings, Inc. (NasdaqGS: GDRX) ('GoodRx'). KSF is investigating whether GoodRx's officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of GoodRx Holdings, Inc. (Nasdaq: GDRX), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
